Clinical Trials Logo

Vaccinia clinical trials

View clinical trials related to Vaccinia.

Filter by:

NCT ID: NCT01374984 Enrolling by invitation - Clinical trials for Complication of Smallpox Vaccination

VA-005 Clinical Outcomes of VIGIV Treatment of Smallpox Vaccination Complications or Vaccinia Infection

Start date: August 2007
Phase:
Study type: Observational

This is a post-marketing study to verify the clinical benefits of VIGIV [CNJ-016, Vaccinia Immune Globulin Intravenous (Human), sterile solution] in the resolution of complications resulting from smallpox vaccination in eligible patients treated with VIGIV.

NCT ID: NCT01329809 Terminated - Clinical trials for Colorectal Carcinoma

Neoadjuvant Study of Recombinant Vaccinia Virus to Treat Metastatic Colorectal Carcinoma in Patients Undergoing Complete Resection of Liver Tumors

Start date: October 2011
Phase: Phase 2
Study type: Interventional

This is a neoadjuvant Phase 2a, open-label trial in patients with metastatic colorectal carcinoma who are undergoing a complete resection of the metastatic colorectal tumors in their liver.

NCT ID: NCT01171651 Completed - Clinical trials for Carcinoma, Hepatocellular

A Study of Recombinant Vaccinia Virus Prior to Sorafenib to Treat Unresectable Primary Hepatocellular Carcinoma

Start date: August 2009
Phase: Phase 2
Study type: Interventional

The purpose of this pilot safety study is to evaluate the safety and tolerability of JX-594 (Pexa-Vec) administered intravenously and intratumorally prior to standard sorafenib therapy.

NCT ID: NCT01169584 Completed - Lymphoma Clinical Trials

Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients

Start date: August 2010
Phase: Phase 1
Study type: Interventional

This is a Phase I, open-label, dose-escalation trial of JX-594 (Pexa-Vec) in pediatric patients with advanced/metastatic, unresectable solid tumors refractory to standard therapy and/or the patient does not tolerate standard therapies. Tumors are likely to include neuroblastoma, lymphoma, Wilms' tumor, rhabdomyosarcoma, Ewing's sarcoma, osteosarcoma, non-rhabdomyosarcoma soft tissue sarcomas, and malignant peripheral nerve sheath tumors. Benign tumors are excluded. These tumor types were selected because evidence of biological activity was observed in cancer cells lines and ex vivo infected primary human tissue samples, specifically pediatric cancer types such as sarcomas and neuroblastomas.

NCT ID: NCT01158157 Completed - Clinical trials for Smallpox Vaccine Adverse Reaction

VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIV

Start date: September 13, 2010
Phase: Phase 3
Study type: Interventional

The purpose of this study is to vaccinate plasma donors with ACAM2000 smallpox vaccine for collection of plasma to be used in the manufacturing of Vaccinia Immune Globulin Intravenous (VIGIV).

NCT ID: NCT01144637 Completed - Smallpox Clinical Trials

A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects

Start date: February 2013
Phase: Phase 3
Study type: Interventional

A randomized, double-blind, placebo-controlled Phase III trial to evaluate immunogenicity and safety of three consecutive production lots of IMVAMUNE® (MVA-BN®) smallpox vaccine in healthy, vaccinia-naïve subjects.

NCT ID: NCT00857493 Completed - Smallpox Clinical Trials

A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects

Start date: June 2009
Phase: Phase 2
Study type: Interventional

A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-Experienced Subjects

NCT ID: NCT00629759 Completed - Neoplasms, Liver Clinical Trials

A Study of Recombinant Vaccinia Virus to Evaluate the Safety and Efficacy of a Transdermal Injection Within the Tumor of Patients With Primary or Metastatic Hepatic Carcinoma

Start date: January 2006
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to determine the maximum tolerable dose (MTD) and/or the maximum feasible dose (MFD), as well as to evaluate the safety of JX-594 (Pexa-Vec) injected within hepatic carcinoma tumors.

NCT ID: NCT00625456 Completed - Lung Cancer Clinical Trials

Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors

Start date: June 2008
Phase: Phase 1
Study type: Interventional

This is a Phase I, open-label, dose-escalation trial in patients with advanced/metastatic solid tumors refractory to standard therapy; tumors may include malignant melanoma, non-small cell lung cancer, renal cell carcinoma, and squamous cell carcinoma of the head and neck. These tumor types were selected because evidence of biological activity was observed in these tumor types in a Phase I study of JX-594 (Pexa-Vec) administered by intratumoral injection in patients with metastatic disease to the liver. Patients will receive treatment at one of five dose levels in a sequential dose-escalating design.

NCT ID: NCT00574977 Completed - Breast Cancer Clinical Trials

Safety Study of Modified Vaccinia Virus to Cancer

Start date: May 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety and maximum tolerated dose from injecting this vaccinia virus into tumors or infusion.